Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Eva Santamaria"'
Autor:
Hugo Arasanz, Carlos Hernández, Ana Bocanegra, Luisa Chocarro, Miren Zuazo, Maria Gato, Karina Ausin, Enrique Santamaría, Joaquín Fernández-Irigoyen, Gonzalo Fernandez, Eva Santamaria, Carlos Rodríguez, Idoia Blanco-Luquin, Ruth Vera, David Escors, Grazyna Kochan
Publikováno v:
Cancers, Vol 12, Iss 8, p 2181 (2020)
Cancer cells acquire resistance to cytotoxic therapies targeting major survival pathways by adapting their metabolism. The AKT pathway is a major regulator of human pancreatic adenocarcinoma progression and a key pharmacological target. The mechanism
Externí odkaz:
https://doaj.org/article/023858e5c082472db0e122c4b6e33531
Autor:
Enrique Conde, Noelia Casares, Uxua Mancheño, Edurne Elizalde, Enric Vercher, Roberto Capozzi, Eva Santamaria, Juan R. Rodriguez-Madoz, Felipe Prosper, Juan J. Lasarte, Teresa Lozano, Sandra Hervas-Stubbs
Publikováno v:
Molecular Therapy. 31:48-65
Regulatory T cells overwhelm conventional T cells in the tumor microenvironment (TME) thanks to a FOXP3-driven metabolic program that allows them to engage different metabolic pathways. Using a melanoma model of adoptive T cell therapy (ACT), we show
Autor:
Carlos Lopez, Naiara Calvo, Teresa Oloriz, Francisco Díaz, Beatriz Jauregui, Nina Soto, Eva Santamaria, Pilar Rodriguez, Maria Rosario Ortas, Antonio Asso
Publikováno v:
Heart Rhythm. 20:S491
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Clinical Pharmacology : Advances and Applications
Universitat Autònoma de Barcelona
Clinical Pharmacology : Advances and Applications
Eva Santamaria,1,2 Iñaki Izquierdo,2 Marta Valle1,3 1Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain; 2Clinical Development, Porfolio & Strategy, Biorhom SL Grupo Uriach, Barcelona,
Autor:
Alexander Finnemore, Jose Maria Herranz, Sergio Barace, Stefany Infante, Matías A Avila, Guillermo Garcia-Porrero, Sara Arcelus, Eva Santamaria, Josepmaria Argemi
Publikováno v:
Journal of Hepatology. 77:S697
Autor:
Sergio Barace, Eva Santamaría, Stefany Infante, Sara Arcelus, Jesus De La Fuente, Enrique Goñi, Ibon Tamayo, Idoia Ochoa, Miguel Sogbe, Bruno Sangro, Mikel Hernaez, Matias A. Avila, Josepmaria Argemi
Publikováno v:
Biomolecules, Vol 14, Iss 6, p 653 (2024)
Whole-tissue transcriptomic analyses have been helpful to characterize molecular subtypes of hepatocellular carcinoma (HCC). Metabolic subtypes of human HCC have been defined, yet whether these different metabolic classes are clinically relevant or d
Externí odkaz:
https://doaj.org/article/849503fa0ca248918b9f5150dce46864
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Journal of Asthma and Allergy
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Universitat Autònoma de Barcelona
Journal of Asthma and Allergy
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Eva Santamaría,1,2 Iñaki Izquierdo,2 Marta Valle,1,3 Jan Vermeulen,4 Paul Potter5 1Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain; 2Clinical Development, R&D, J. Uriach y Compañía, S.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65c30b485443c7d4876ebfaccbed984d
https://ddd.uab.cat/record/228011
https://ddd.uab.cat/record/228011
Autor:
Laura M. Laiglesia, Xavier Escoté, Neira Sáinz, Elisa Felix-Soriano, Eva Santamaría, María Collantes, Marta Fernández-Galilea, Ignacio Colón-Mesa, Leyre Martínez-Fernández, Tania Quesada-López, Sergio Quesada-Vázquez, Carlos Rodríguez-Ortigosa, José M. Arbones-Mainar, Ángela M. Valverde, J Alfredo Martínez, Jesmond Dalli, Laura Herrero, Silvia Lorente-Cebrián, Francesc Villarroya, María J. Moreno-Aliaga
Publikováno v:
Molecular Metabolism, Vol 74, Iss , Pp 101749- (2023)
Objective: Maresin 1 (MaR1) is a docosahexaenoic acid-derived proresolving lipid mediator with insulin-sensitizing and anti-steatosis properties. Here, we aim to unravel MaR1 actions on brown adipose tissue (BAT) activation and white adipose tissue (
Externí odkaz:
https://doaj.org/article/22820310ff864737969835f5345a7e5e
Publikováno v:
PLoS One
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
PLoS ONE
PLoS ONE, Vol 12, Iss 4, p e0176091 (2017)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
PLoS ONE
PLoS ONE, Vol 12, Iss 4, p e0176091 (2017)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Aims To optimise a pharmacokinetic (PK) study design of rupatadine for 2–5 year olds by using a population PK model developed with data from a study in 6–11 year olds. The design optimisation was driven by the need to avoid children’s discomfor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70a5bcf10f97de661cb004c9e7b18575
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6511
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6511
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0163020 (2016)
PLoS ONE
PLoS ONE
Introduction Rupatadine is a marketed second generation antihistamine, with anti-PAF activity, indicated for symptomatic treatment of allergic rhinitis and urticaria. This study was conducted to evaluate the pharmacokinetics (PK), pharmacodynamics (P